[1] |
Bernard V, Young J, Binart N. Prolactin-a pleiotropic factor in health and disease[J]. Nat Rev Endocrinol,2019,15(6):356-365.
|
[2] |
中华医学会妇产科学分会内分泌学组. 女性高催乳素血症诊治共识[J]. 中华妇产科杂志,2016,51(3):161-168.
|
[3] |
Samperi I, Lithgow K, Karavitaki N. Hyperprolactinaemia[J]. J Clin Med,2019,8(12):1-24.
|
[4] |
Vilar L, Vilar CF, Lyra R, et al. Pitfalls in the diagnostic evaluation of hyperprolactinemia[J]. Neuroendocrinology,2019,109(1):7-19.
|
[5] |
Chanson P, Maiter D. The epidemiology, diagnosis and treatment of prolactinomas: the old and the new[J]. Best Pract Res Clin Endocrinol Metab,2019,33(2):1-22.
|
[6] |
Auriemma RS, Pirchio R, Pivonello C, et al. Approach to the patient with prolactinoma[J]. J Clin Endocrinol Metab,2023,108(9):2400-2423.
|
[7] |
Glezer A, Bronstein MD. Prolactinomas in pregnancy: considerations before conception and during pregnancy[J]. Pituitary,2020,23(1):65-69.
|
[8] |
Levin G, Rottenstreich A. Prolactin, prolactin disorders, and dopamine agonists during pregnancy[J]. Hormones (Athens),2019,18(2):137-139.
|
[9] |
Kalsi AK, Halder A, Jain M, et al. Prevalence and reproductive manifestations of macroprolactinemia[J]. Endocrine,2019,63(2):332-340.
|
[10] |
Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline[J]. J Clin Endocrinol Metab,2011,96(2):273-288.
|
[11] |
Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma[J]. Eur J Endocrinol,2015,172(5):R205-213.
|
[12] |
Ruiz-Velasco V, Tolis G. Pregnancy in hyperprolactinemic women[J]. Fertil Steril,1984,41(6):793-805.
|
[13] |
Lambert K, Rees K, Seed PT, et al. Macroprolactinomas and nonfunctioning pituitary adenomas and pregnancy outcomes[J]. Obstet Gynecol,2017,129(1):185-194.
|
[14] |
Montejo ÁL, Arango C, Bernardo M, et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics[J]. Front Neuroendocrinol,2017,45:25-34.
|
[15] |
Lu Z, Sun Y, Zhang Y, et al. Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis[J]. Transl Psychiatry,2022,12(1):1-14.
|
[16] |
Chanson P. Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists[J]. Best Pract Res Clin Endocrinol Metab,2022,36(6):1-11.
|